Cargando…

Management of Hepple Stage V Osteochondral Lesion of the Talus with a Platelet-Rich Plasma Scaffold

There has been no consensus on the treatment or prognosis of Hepple stage V osteochondral lesions of the talus (OLTs), especially for lesions greater than 1.5 cm(2) in size. The objective of this study was to investigate the clinical outcomes achieved upon application of a platelet-rich plasma (PRP)...

Descripción completa

Detalles Bibliográficos
Autores principales: Gu, Wenqi, Li, Tanzhu, Shi, Zhongmin, Mei, Guohua, Xue, Jianfeng, Zou, Jian, Wang, Xiaokang, Zhang, Haotong, Xu, Hongwei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5376404/
https://www.ncbi.nlm.nih.gov/pubmed/28401159
http://dx.doi.org/10.1155/2017/6525373
_version_ 1782519150690697216
author Gu, Wenqi
Li, Tanzhu
Shi, Zhongmin
Mei, Guohua
Xue, Jianfeng
Zou, Jian
Wang, Xiaokang
Zhang, Haotong
Xu, Hongwei
author_facet Gu, Wenqi
Li, Tanzhu
Shi, Zhongmin
Mei, Guohua
Xue, Jianfeng
Zou, Jian
Wang, Xiaokang
Zhang, Haotong
Xu, Hongwei
author_sort Gu, Wenqi
collection PubMed
description There has been no consensus on the treatment or prognosis of Hepple stage V osteochondral lesions of the talus (OLTs), especially for lesions greater than 1.5 cm(2) in size. The objective of this study was to investigate the clinical outcomes achieved upon application of a platelet-rich plasma (PRP) scaffold with a cancellous bone autograft for Hepple stage V OLTs. Fourteen patients (mean age, 39 years) were treated with a cancellous bone graft and a PRP scaffold between 2013 and 2015. The mean time to surgical treatment was 23.5 months. Ankle X-ray and magnetic resonance imaging were performed at the final follow-up. Functional outcomes were evaluated according to the Visual Analog Scale (VAS) score, American Orthopaedic Foot and Ankle Society (AOFAS) score, and Short Form 36 (SF-36) score. The range of motion (ROM) of the ankle joint and complications also were recorded. Thirteen patients completed the full follow-up, with a mean follow-up duration of 18 months. MRI demonstrated the complete regeneration of subchondral bone and cartilage in all patients. The postoperative VAS, AOFAS ankle and hindfoot, and SF-36 scores were improved significantly (all P < 0.001) without obvious complications. We suggest that, for the Hepple stage V OLTs, management with cancellous bone graft and PRP scaffold may be a safe and effective treatment.
format Online
Article
Text
id pubmed-5376404
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-53764042017-04-11 Management of Hepple Stage V Osteochondral Lesion of the Talus with a Platelet-Rich Plasma Scaffold Gu, Wenqi Li, Tanzhu Shi, Zhongmin Mei, Guohua Xue, Jianfeng Zou, Jian Wang, Xiaokang Zhang, Haotong Xu, Hongwei Biomed Res Int Clinical Study There has been no consensus on the treatment or prognosis of Hepple stage V osteochondral lesions of the talus (OLTs), especially for lesions greater than 1.5 cm(2) in size. The objective of this study was to investigate the clinical outcomes achieved upon application of a platelet-rich plasma (PRP) scaffold with a cancellous bone autograft for Hepple stage V OLTs. Fourteen patients (mean age, 39 years) were treated with a cancellous bone graft and a PRP scaffold between 2013 and 2015. The mean time to surgical treatment was 23.5 months. Ankle X-ray and magnetic resonance imaging were performed at the final follow-up. Functional outcomes were evaluated according to the Visual Analog Scale (VAS) score, American Orthopaedic Foot and Ankle Society (AOFAS) score, and Short Form 36 (SF-36) score. The range of motion (ROM) of the ankle joint and complications also were recorded. Thirteen patients completed the full follow-up, with a mean follow-up duration of 18 months. MRI demonstrated the complete regeneration of subchondral bone and cartilage in all patients. The postoperative VAS, AOFAS ankle and hindfoot, and SF-36 scores were improved significantly (all P < 0.001) without obvious complications. We suggest that, for the Hepple stage V OLTs, management with cancellous bone graft and PRP scaffold may be a safe and effective treatment. Hindawi 2017 2017-03-16 /pmc/articles/PMC5376404/ /pubmed/28401159 http://dx.doi.org/10.1155/2017/6525373 Text en Copyright © 2017 Wenqi Gu et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Clinical Study
Gu, Wenqi
Li, Tanzhu
Shi, Zhongmin
Mei, Guohua
Xue, Jianfeng
Zou, Jian
Wang, Xiaokang
Zhang, Haotong
Xu, Hongwei
Management of Hepple Stage V Osteochondral Lesion of the Talus with a Platelet-Rich Plasma Scaffold
title Management of Hepple Stage V Osteochondral Lesion of the Talus with a Platelet-Rich Plasma Scaffold
title_full Management of Hepple Stage V Osteochondral Lesion of the Talus with a Platelet-Rich Plasma Scaffold
title_fullStr Management of Hepple Stage V Osteochondral Lesion of the Talus with a Platelet-Rich Plasma Scaffold
title_full_unstemmed Management of Hepple Stage V Osteochondral Lesion of the Talus with a Platelet-Rich Plasma Scaffold
title_short Management of Hepple Stage V Osteochondral Lesion of the Talus with a Platelet-Rich Plasma Scaffold
title_sort management of hepple stage v osteochondral lesion of the talus with a platelet-rich plasma scaffold
topic Clinical Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5376404/
https://www.ncbi.nlm.nih.gov/pubmed/28401159
http://dx.doi.org/10.1155/2017/6525373
work_keys_str_mv AT guwenqi managementofhepplestagevosteochondrallesionofthetaluswithaplateletrichplasmascaffold
AT litanzhu managementofhepplestagevosteochondrallesionofthetaluswithaplateletrichplasmascaffold
AT shizhongmin managementofhepplestagevosteochondrallesionofthetaluswithaplateletrichplasmascaffold
AT meiguohua managementofhepplestagevosteochondrallesionofthetaluswithaplateletrichplasmascaffold
AT xuejianfeng managementofhepplestagevosteochondrallesionofthetaluswithaplateletrichplasmascaffold
AT zoujian managementofhepplestagevosteochondrallesionofthetaluswithaplateletrichplasmascaffold
AT wangxiaokang managementofhepplestagevosteochondrallesionofthetaluswithaplateletrichplasmascaffold
AT zhanghaotong managementofhepplestagevosteochondrallesionofthetaluswithaplateletrichplasmascaffold
AT xuhongwei managementofhepplestagevosteochondrallesionofthetaluswithaplateletrichplasmascaffold